Kathy Mulgrew

2.3k total citations
24 papers, 980 citations indexed

About

Kathy Mulgrew is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Kathy Mulgrew has authored 24 papers receiving a total of 980 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in Kathy Mulgrew's work include CAR-T cell therapy research (14 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Virus-based gene therapy research (6 papers). Kathy Mulgrew is often cited by papers focused on CAR-T cell therapy research (14 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Virus-based gene therapy research (6 papers). Kathy Mulgrew collaborates with scholars based in United States, United Kingdom and Switzerland. Kathy Mulgrew's co-authors include Scott A. Hammond, Kris F. Sachsenmeier, Michael Kaleko, Susan C. Stevenson, Kelly McGlinchey, Theodore A Smith, Stacy Fuhrmann, Neeraja Idamakanti, Melissa Damschroder and Jennifer Marshall-Neff and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Virology.

In The Last Decade

Kathy Mulgrew

23 papers receiving 948 citations

Peers

Kathy Mulgrew
Jan Endell Germany
Nan Ring United States
Yutaka Kawakami Japan
Naveen Dakappagari United States
Andreas Wadle Germany
Felix S. Lichtenegger Germany
Gabrielle J. Grundy United Kingdom
Sheila Spada United States
Catherine S. Wegner Norway
Elixabet Bolaños Spain
Jan Endell Germany
Kathy Mulgrew
Citations per year, relative to Kathy Mulgrew Kathy Mulgrew (= 1×) peers Jan Endell

Countries citing papers authored by Kathy Mulgrew

Since Specialization
Citations

This map shows the geographic impact of Kathy Mulgrew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy Mulgrew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy Mulgrew more than expected).

Fields of papers citing papers by Kathy Mulgrew

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathy Mulgrew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy Mulgrew. The network helps show where Kathy Mulgrew may publish in the future.

Co-authorship network of co-authors of Kathy Mulgrew

This figure shows the co-authorship network connecting the top 25 collaborators of Kathy Mulgrew. A scholar is included among the top collaborators of Kathy Mulgrew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathy Mulgrew. Kathy Mulgrew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Malhotra, Deepali, Eleanor Clancy‐Thompson, Bilal Omar, et al.. (2022). 469 Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT. Regular and Young Investigator Award Abstracts. A489–A489. 5 indexed citations
2.
Harper, James A., Shannon Burke, Jon Travers, et al.. (2021). Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. Molecular Cancer Therapeutics. 20(9). 1723–1734. 10 indexed citations
3.
Hurt, Elaine M., Suneetha B. Thomas, Kathy Mulgrew, et al.. (2021). Abstract 1828: AZD8853: A novel antibody targeting GDF15 for immunotherapy refractory tumors. Cancer Research. 81(13_Supplement). 1828–1828. 2 indexed citations
4.
Galvani, Elena, Kathy Mulgrew, Chris M. Rands, et al.. (2021). Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models. Journal for ImmunoTherapy of Cancer. 9(6). e002894–e002894. 5 indexed citations
5.
Harper, James A., Nicola Rath, Shannon Burke, et al.. (2020). Abstract 6535: A recombinant Newcastle disease virus expressing IL-12 has potent pre-clinical immunomodulatory and anti tumor properties. Cancer Research. 80(16_Supplement). 6535–6535. 1 indexed citations
6.
Rios‐Doria, Jonathan, Jay Harper, Raymond Rothstein, et al.. (2017). Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Research. 77(10). 2686–2698. 91 indexed citations
7.
Durham, Nicholas M., Kathy Mulgrew, Kelly McGlinchey, et al.. (2017). Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Molecular Therapy. 25(8). 1917–1932. 51 indexed citations
8.
Mazor, Yariv, Kris F. Sachsenmeier, Chunning Yang, et al.. (2017). Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Scientific Reports. 7(1). 40098–40098. 89 indexed citations
9.
Hay, Carl, Erin Sult, Qihui Huang, et al.. (2016). Targeting CD73 in the tumor microenvironment with MEDI9447. OncoImmunology. 5(8). e1208875–e1208875. 229 indexed citations
10.
Hay, Carl, Erin Sult, Qihui Huang, et al.. (2015). Abstract 285: MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment. Cancer Research. 75(15_Supplement). 285–285. 10 indexed citations
11.
12.
Stewart, Ross, Michelle Morrow, Matthieu Chodorge, et al.. (2011). Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development. Cancer Research. 71(8_Supplement). LB–158. 7 indexed citations
13.
Fuhrmann, Stacy, Maria Amann, Kathy Mulgrew, et al.. (2010). Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas. Cancer Research. 70(8_Supplement). 5625–5625. 1 indexed citations
14.
Bruckheimer, Elizabeth, Christine Fazenbaker, Sandra Gallagher, et al.. (2009). Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors. Neoplasia. 11(6). 509–IN2. 29 indexed citations
15.
Lutterbuese, Ralf, Tobias Raum, Roman Kischel, et al.. (2009). Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA. Journal of Immunotherapy. 32(4). 341–352. 64 indexed citations
16.
Mulgrew, Kathy, David J. Stewart, Wendy L. Trigona, et al.. (2008). Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models. Cancer Research. 68. 2131–2131. 2 indexed citations
17.
Mulgrew, Kathy, Krista Kinneer, Melissa Damschroder, et al.. (2006). Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™. Molecular Cancer Therapeutics. 5(12). 3122–3129. 83 indexed citations
18.
Nyanguile, Origène, et al.. (2003). Synthesis of adenoviral targeting molecules by intein-mediated protein ligation. Gene Therapy. 10(16). 1362–1369. 15 indexed citations
19.
Smith, Theodore A, Neeraja Idamakanti, Michele L. Rollence, et al.. (2003). Adenovirus Serotype 5 Fiber Shaft Influences In Vivo Gene Transfer in Mice. Human Gene Therapy. 14(8). 777–787. 168 indexed citations
20.
Kim, Jin, Theodore A Smith, Neeraja Idamakanti, et al.. (2002). Targeting Adenoviral Vectors by Using the Extracellular Domain of the Coxsackie-Adenovirus Receptor: Improved Potency via Trimerization. Journal of Virology. 76(4). 1892–1903. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Endell Breakdown of academic impact, for papers by Nan Ring Breakdown of academic impact, for papers by Yutaka Kawakami Breakdown of academic impact, for papers by Naveen Dakappagari Breakdown of academic impact, for papers by Andreas Wadle Breakdown of academic impact, for papers by Felix S. Lichtenegger Breakdown of academic impact, for papers by Gabrielle J. Grundy Breakdown of academic impact, for papers by Sheila Spada Breakdown of academic impact, for papers by Catherine S. Wegner Breakdown of academic impact, for papers by Elixabet Bolaños
Rankless by CCL
2026